Eintrag weiter verarbeiten
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , |
| In: | Clinical Cancer Research, 25, 2019, 2, S. 844-855 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Agnihotri, Sameer Mansouri, Sheila Burrell, Kelly Li, Mira Mamatjan, Yasin Liu, Jeff Nejad, Romina Kumar, Sushil Jalali, Shahrzad Singh, Sanjay K. Vartanian, Alenoush Chen, Eric Xueyu Karimi, Shirin Singh, Olivia Bunda, Severa Mansouri, Alireza Aldape, Kenneth D. Zadeh, Gelareh Agnihotri, Sameer Mansouri, Sheila Burrell, Kelly Li, Mira Mamatjan, Yasin Liu, Jeff Nejad, Romina Kumar, Sushil Jalali, Shahrzad Singh, Sanjay K. Vartanian, Alenoush Chen, Eric Xueyu Karimi, Shirin Singh, Olivia Bunda, Severa Mansouri, Alireza Aldape, Kenneth D. Zadeh, Gelareh |
|---|---|
| author |
Agnihotri, Sameer Mansouri, Sheila Burrell, Kelly Li, Mira Mamatjan, Yasin Liu, Jeff Nejad, Romina Kumar, Sushil Jalali, Shahrzad Singh, Sanjay K. Vartanian, Alenoush Chen, Eric Xueyu Karimi, Shirin Singh, Olivia Bunda, Severa Mansouri, Alireza Aldape, Kenneth D. Zadeh, Gelareh |
| spellingShingle |
Agnihotri, Sameer Mansouri, Sheila Burrell, Kelly Li, Mira Mamatjan, Yasin Liu, Jeff Nejad, Romina Kumar, Sushil Jalali, Shahrzad Singh, Sanjay K. Vartanian, Alenoush Chen, Eric Xueyu Karimi, Shirin Singh, Olivia Bunda, Severa Mansouri, Alireza Aldape, Kenneth D. Zadeh, Gelareh Clinical Cancer Research Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells Cancer Research Oncology |
| author_sort |
agnihotri, sameer |
| spelling |
Agnihotri, Sameer Mansouri, Sheila Burrell, Kelly Li, Mira Mamatjan, Yasin Liu, Jeff Nejad, Romina Kumar, Sushil Jalali, Shahrzad Singh, Sanjay K. Vartanian, Alenoush Chen, Eric Xueyu Karimi, Shirin Singh, Olivia Bunda, Severa Mansouri, Alireza Aldape, Kenneth D. Zadeh, Gelareh 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-18-1854 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>Hexokinase II (HK2) protein expression is elevated in glioblastoma (GBM), and we have shown that HK2 could serve as an effective therapeutic target for GBM. Here, we interrogated compounds that target HK2 effectively and restrict tumor growth in cell lines, patient-derived glioma stem cells (GSCs), and mouse models of GBM.</jats:p> <jats:p>Experimental Design: We performed a screen using a set of 15 drugs that were predicted to inhibit the HK2-associated gene signature. We next determined the EC50 of the compounds by treating glioma cell lines and GSCs. Selected compounds showing significant impact in vitro were used to treat mice and examine their effect on survival and tumor characteristics. The effect of compounds on the metabolic activity in glioma cells was also assessed in vitro.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>This screen identified the azole class of antifungals as inhibitors of tumor metabolism. Among the compounds tested, ketoconazole and posaconazole displayed the greatest inhibitory effect on GBM both in vitro and in vivo. Treatment of mice bearing GBM with ketoconazole and posaconazole increased their survival, reduced tumor cell proliferation, and decreased tumor metabolism. In addition, treatment with azoles resulted in increased proportion of apoptotic cells.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Overall, we provide evidence that azoles exert their effect by targeting genes and pathways regulated by HK2. These findings shed light on the action of azoles in GBM. Combined with existing literature and preclinical results, these data support the value of repurposing azoles in GBM clinical trials.</jats:p> </jats:sec> Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-18-1854 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE4NTQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE4NTQ |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Association for Cancer Research (AACR), 2019 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2019 |
| issn |
1557-3265 1078-0432 |
| issn_str_mv |
1557-3265 1078-0432 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
agnihotri2019ketoconazoleandposaconazoleselectivelytargethk2expressingglioblastomacells |
| publishDateSort |
2019 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_unstemmed |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_full |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_fullStr |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_full_unstemmed |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_short |
Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_sort |
ketoconazole and posaconazole selectively target hk2-expressing glioblastoma cells |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-18-1854 |
| publishDate |
2019 |
| physical |
844-855 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Purpose:</jats:title>
<jats:p>Hexokinase II (HK2) protein expression is elevated in glioblastoma (GBM), and we have shown that HK2 could serve as an effective therapeutic target for GBM. Here, we interrogated compounds that target HK2 effectively and restrict tumor growth in cell lines, patient-derived glioma stem cells (GSCs), and mouse models of GBM.</jats:p>
<jats:p>Experimental Design: We performed a screen using a set of 15 drugs that were predicted to inhibit the HK2-associated gene signature. We next determined the EC50 of the compounds by treating glioma cell lines and GSCs. Selected compounds showing significant impact in vitro were used to treat mice and examine their effect on survival and tumor characteristics. The effect of compounds on the metabolic activity in glioma cells was also assessed in vitro.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>This screen identified the azole class of antifungals as inhibitors of tumor metabolism. Among the compounds tested, ketoconazole and posaconazole displayed the greatest inhibitory effect on GBM both in vitro and in vivo. Treatment of mice bearing GBM with ketoconazole and posaconazole increased their survival, reduced tumor cell proliferation, and decreased tumor metabolism. In addition, treatment with azoles resulted in increased proportion of apoptotic cells.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>Overall, we provide evidence that azoles exert their effect by targeting genes and pathways regulated by HK2. These findings shed light on the action of azoles in GBM. Combined with existing literature and preclinical results, these data support the value of repurposing azoles in GBM clinical trials.</jats:p>
</jats:sec> |
| container_issue |
2 |
| container_start_page |
844 |
| container_title |
Clinical Cancer Research |
| container_volume |
25 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792346499631284228 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:40:04.16Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Ketoconazole+and+Posaconazole+Selectively+Target+HK2-expressing+Glioblastoma+Cells&rft.date=2019-01-15&genre=article&issn=1557-3265&volume=25&issue=2&spage=844&epage=855&pages=844-855&jtitle=Clinical+Cancer+Research&atitle=Ketoconazole+and+Posaconazole+Selectively+Target+HK2-expressing+Glioblastoma+Cells&aulast=Zadeh&aufirst=Gelareh&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-18-1854&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792346499631284228 |
| author | Agnihotri, Sameer, Mansouri, Sheila, Burrell, Kelly, Li, Mira, Mamatjan, Yasin, Liu, Jeff, Nejad, Romina, Kumar, Sushil, Jalali, Shahrzad, Singh, Sanjay K., Vartanian, Alenoush, Chen, Eric Xueyu, Karimi, Shirin, Singh, Olivia, Bunda, Severa, Mansouri, Alireza, Aldape, Kenneth D., Zadeh, Gelareh |
| author_facet | Agnihotri, Sameer, Mansouri, Sheila, Burrell, Kelly, Li, Mira, Mamatjan, Yasin, Liu, Jeff, Nejad, Romina, Kumar, Sushil, Jalali, Shahrzad, Singh, Sanjay K., Vartanian, Alenoush, Chen, Eric Xueyu, Karimi, Shirin, Singh, Olivia, Bunda, Severa, Mansouri, Alireza, Aldape, Kenneth D., Zadeh, Gelareh, Agnihotri, Sameer, Mansouri, Sheila, Burrell, Kelly, Li, Mira, Mamatjan, Yasin, Liu, Jeff, Nejad, Romina, Kumar, Sushil, Jalali, Shahrzad, Singh, Sanjay K., Vartanian, Alenoush, Chen, Eric Xueyu, Karimi, Shirin, Singh, Olivia, Bunda, Severa, Mansouri, Alireza, Aldape, Kenneth D., Zadeh, Gelareh |
| author_sort | agnihotri, sameer |
| container_issue | 2 |
| container_start_page | 844 |
| container_title | Clinical Cancer Research |
| container_volume | 25 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>Hexokinase II (HK2) protein expression is elevated in glioblastoma (GBM), and we have shown that HK2 could serve as an effective therapeutic target for GBM. Here, we interrogated compounds that target HK2 effectively and restrict tumor growth in cell lines, patient-derived glioma stem cells (GSCs), and mouse models of GBM.</jats:p> <jats:p>Experimental Design: We performed a screen using a set of 15 drugs that were predicted to inhibit the HK2-associated gene signature. We next determined the EC50 of the compounds by treating glioma cell lines and GSCs. Selected compounds showing significant impact in vitro were used to treat mice and examine their effect on survival and tumor characteristics. The effect of compounds on the metabolic activity in glioma cells was also assessed in vitro.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>This screen identified the azole class of antifungals as inhibitors of tumor metabolism. Among the compounds tested, ketoconazole and posaconazole displayed the greatest inhibitory effect on GBM both in vitro and in vivo. Treatment of mice bearing GBM with ketoconazole and posaconazole increased their survival, reduced tumor cell proliferation, and decreased tumor metabolism. In addition, treatment with azoles resulted in increased proportion of apoptotic cells.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Overall, we provide evidence that azoles exert their effect by targeting genes and pathways regulated by HK2. These findings shed light on the action of azoles in GBM. Combined with existing literature and preclinical results, these data support the value of repurposing azoles in GBM clinical trials.</jats:p> </jats:sec> |
| doi_str_mv | 10.1158/1078-0432.ccr-18-1854 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTE4LTE4NTQ |
| imprint | American Association for Cancer Research (AACR), 2019 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 1557-3265, 1078-0432 |
| issn_str_mv | 1557-3265, 1078-0432 |
| language | English |
| last_indexed | 2024-03-01T17:40:04.16Z |
| match_str | agnihotri2019ketoconazoleandposaconazoleselectivelytargethk2expressingglioblastomacells |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 844-855 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Agnihotri, Sameer Mansouri, Sheila Burrell, Kelly Li, Mira Mamatjan, Yasin Liu, Jeff Nejad, Romina Kumar, Sushil Jalali, Shahrzad Singh, Sanjay K. Vartanian, Alenoush Chen, Eric Xueyu Karimi, Shirin Singh, Olivia Bunda, Severa Mansouri, Alireza Aldape, Kenneth D. Zadeh, Gelareh 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-18-1854 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>Hexokinase II (HK2) protein expression is elevated in glioblastoma (GBM), and we have shown that HK2 could serve as an effective therapeutic target for GBM. Here, we interrogated compounds that target HK2 effectively and restrict tumor growth in cell lines, patient-derived glioma stem cells (GSCs), and mouse models of GBM.</jats:p> <jats:p>Experimental Design: We performed a screen using a set of 15 drugs that were predicted to inhibit the HK2-associated gene signature. We next determined the EC50 of the compounds by treating glioma cell lines and GSCs. Selected compounds showing significant impact in vitro were used to treat mice and examine their effect on survival and tumor characteristics. The effect of compounds on the metabolic activity in glioma cells was also assessed in vitro.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>This screen identified the azole class of antifungals as inhibitors of tumor metabolism. Among the compounds tested, ketoconazole and posaconazole displayed the greatest inhibitory effect on GBM both in vitro and in vivo. Treatment of mice bearing GBM with ketoconazole and posaconazole increased their survival, reduced tumor cell proliferation, and decreased tumor metabolism. In addition, treatment with azoles resulted in increased proportion of apoptotic cells.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Overall, we provide evidence that azoles exert their effect by targeting genes and pathways regulated by HK2. These findings shed light on the action of azoles in GBM. Combined with existing literature and preclinical results, these data support the value of repurposing azoles in GBM clinical trials.</jats:p> </jats:sec> Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells Clinical Cancer Research |
| spellingShingle | Agnihotri, Sameer, Mansouri, Sheila, Burrell, Kelly, Li, Mira, Mamatjan, Yasin, Liu, Jeff, Nejad, Romina, Kumar, Sushil, Jalali, Shahrzad, Singh, Sanjay K., Vartanian, Alenoush, Chen, Eric Xueyu, Karimi, Shirin, Singh, Olivia, Bunda, Severa, Mansouri, Alireza, Aldape, Kenneth D., Zadeh, Gelareh, Clinical Cancer Research, Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells, Cancer Research, Oncology |
| title | Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_full | Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_fullStr | Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_full_unstemmed | Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_short | Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| title_sort | ketoconazole and posaconazole selectively target hk2-expressing glioblastoma cells |
| title_unstemmed | Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-18-1854 |